Cargando…
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
Immune checkpoint blockade (ICB) therapy for cancer has achieved great success both in clinical results and on the market. At the same time, success drives more attention from scientists to improve it. However, only a small portion of patients are responsive to this therapy, and it comes with a uniq...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142459/ https://www.ncbi.nlm.nih.gov/pubmed/37106400 http://dx.doi.org/10.1186/s40779-023-00455-x |
_version_ | 1785033618700107776 |
---|---|
author | Ma, Guang-Long Lin, Wei-Feng |
author_facet | Ma, Guang-Long Lin, Wei-Feng |
author_sort | Ma, Guang-Long |
collection | PubMed |
description | Immune checkpoint blockade (ICB) therapy for cancer has achieved great success both in clinical results and on the market. At the same time, success drives more attention from scientists to improve it. However, only a small portion of patients are responsive to this therapy, and it comes with a unique spectrum of side effects termed immune-related adverse events (irAEs). The use of nanotechnology could improve ICBs’ delivery to the tumor, assist them in penetrating deeper into tumor tissues and alleviate their irAEs. Liposomal nanomedicine has been investigated and used for decades, and is well-recognized as the most successful nano-drug delivery system. The successful combination of ICB with liposomal nanomedicine could help improve the efficacy of ICB therapy. In this review, we highlighted recent studies using liposomal nanomedicine (including new emerging exosomes and their inspired nano-vesicles) in associating ICB therapy. |
format | Online Article Text |
id | pubmed-10142459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101424592023-04-29 Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy Ma, Guang-Long Lin, Wei-Feng Mil Med Res Review Immune checkpoint blockade (ICB) therapy for cancer has achieved great success both in clinical results and on the market. At the same time, success drives more attention from scientists to improve it. However, only a small portion of patients are responsive to this therapy, and it comes with a unique spectrum of side effects termed immune-related adverse events (irAEs). The use of nanotechnology could improve ICBs’ delivery to the tumor, assist them in penetrating deeper into tumor tissues and alleviate their irAEs. Liposomal nanomedicine has been investigated and used for decades, and is well-recognized as the most successful nano-drug delivery system. The successful combination of ICB with liposomal nanomedicine could help improve the efficacy of ICB therapy. In this review, we highlighted recent studies using liposomal nanomedicine (including new emerging exosomes and their inspired nano-vesicles) in associating ICB therapy. BioMed Central 2023-04-28 /pmc/articles/PMC10142459/ /pubmed/37106400 http://dx.doi.org/10.1186/s40779-023-00455-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Ma, Guang-Long Lin, Wei-Feng Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy |
title | Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy |
title_full | Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy |
title_fullStr | Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy |
title_full_unstemmed | Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy |
title_short | Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy |
title_sort | immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142459/ https://www.ncbi.nlm.nih.gov/pubmed/37106400 http://dx.doi.org/10.1186/s40779-023-00455-x |
work_keys_str_mv | AT maguanglong immunecheckpointinhibitionmediatedwithliposomalnanomedicineforcancertherapy AT linweifeng immunecheckpointinhibitionmediatedwithliposomalnanomedicineforcancertherapy |